20:17:19 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:HOOK - HOOKIPA PHARMA INC - https://www.redhook.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
HOOK - Q0.91.16·1.200.21.14196.02123521.1402  1.15  1.136.635  0.72119:52:0816:0515 min RT 2¢

Recent Trades - Last 10 of 352
Time ETExPriceChangeVolume
19:52:08Q1.200.0620
19:51:52Q1.19990.05991
19:48:19Q1.200.0615
19:47:12Q1.200.065
19:47:03Q1.200.0630
19:40:06Q1.200.0615
19:18:58Q1.180.0415
19:16:37Q1.180.04175
19:16:01Q1.180.04300
19:15:37Q1.180.04400

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-18 16:05U:HOOKNews ReleaseHOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
2025-01-30 07:00U:HOOKNews ReleaseHOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
2025-01-07 16:05U:HOOKNews ReleaseHOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements
2024-11-14 16:05U:HOOKNews ReleaseHOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates
2024-11-11 16:05U:HOOKNews ReleaseHOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker
2024-10-31 09:17U:HOOKNews ReleaseHOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
2024-10-30 07:30U:HOOKNews ReleaseHOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
2024-09-24 07:30U:HOOKNews ReleaseHOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
2024-08-30 08:00U:HOOKNews ReleaseHOOKIPA Pharma Announces Board of Directors Changes
2024-08-28 08:57U:HOOKNews ReleaseHOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
2024-08-08 16:30U:HOOKNews ReleaseHOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
2024-07-22 08:30U:HOOKNews ReleaseHOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200